Bortezomib (Velcade™) in the Treatment of Multiple Myeloma by Field-Smith, Antonia et al.
Therapeutics and Clinical Risk Management 2006:2(3) 271–279
© 2006 Dove Medical Press Limited. All rights reserved
271
REVIEW
Abstract: The introduction of bortezomib, a novel first-in-class proteasome inhibitor, has
been a major break through in the treatment of multiple myeloma. It is currently approved for
the treatment of myeloma in the relapsed setting post transplant or as a second line treatment
in patients unsuitable for transplantation. In pre-clinical studies bortezomib showed a number
of different anti-myeloma effects including disruption of the cell cycle and induction of
apoptosis, alteration of the bone marrow microenvironment and inhibition of nuclear factor
kappa B (NFκB). Due to its novel mechanism of action, bortezomib has been shown to induce
responses in previously refractory patients (including those with poor risk cytogenetics), and
results in an increased progression free and overall survival in relapsed patients when compared
with dexamethasone treatment alone. It is well tolerated and can be administered in the
outpatient setting with manageable toxicities. Peripheral neuropathy is the most common
dose limiting toxicity and thrombocytopenia can generally be managed with platelet
transfusions without reducing or omitting doses. Bortezomib shows a synergistic effect in
combination with dexamethasone and also sensitises myeloma cells to the effects of other
chemotherapeutic agents with major response rates of over 50% being shown in the relapsed
setting. Initial data from ongoing trials in front line therapy are encouraging with response
rates of 80%–90% when bortezomib is given in combination with other agents and importantly,
the ability to mobilize peripheral blood stem cells is not impaired.
Keywords: myeloma, bortezomib, proteasome inhibition, treatment
Introduction
Much has been learnt about multiple myeloma pathobiology over the last decade.
We have elucidated many of the important growth and survival pathways and
understand in some detail the relationship between the plasma cell and the bone
marrow microenvironment. The current emphasis of research is to translate these
findings into the clinic and to develop novel targeted treatment approaches to improve
patient outcome. Inhibition of the proteasome represents a completely new approach
to the treatment of myeloma with studies demonstrating that this strategy is effective
at killing myeloma cells that are otherwise resistant to conventional lines of therapy.
Bortezomib is the first proteasome inhibitor to be approved for the treatment of
myeloma and represents a step forward in the management of these patients. Phase
III data from the landmark APEX trial demonstrate a significant survival advantage
in patients with relapsed multiple myeloma treated with bortezomib compared with
those treated with dexamethasone alone (Richardson et al 2005a). Since its approval
by the US Food and Drug Administration (FDA) in 2003 there has been rapid clinical
development and it is now approved in over 50 countries worldwide. This review
aims to discuss the data supporting the use of bortezomib in the treatment of myeloma,
as well as highlighting some of the more practical issues surrounding its use in the
clinical setting.
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What is bortezomib and how does
it work?
Bortezomib, formerly known as PS-341, is a boron containing
molecule that specifically and reversibly inhibits the threonine
residue of the 26S proteasome, an enzyme complex that plays
a key role in the cell by regulating protein degradation in a
controlled fashion. Proteins that are no longer required,
including those involved in cell cycle control, apoptosis and
cell signaling, are tagged with ubiquitin which directs them to
the proteasome which subsequently degrades them. This
process maintains the balance of inhibitory and stimulatory
proteins involved in cell cycle, thus inhibition of the proteasome
results in a loss of the tight control of the process with a build
up of cell cycle and regulatory proteins leading to cell death
(Adams et al 1999; Adams 2004). Recent reports also suggest
that bortezomib may disregulate intracellular calcium
metabolism  resulting in caspase activation and apoptosis
(Landowski et al 2005).
Bortezomib has potential as a chemotherapeutic agent in
many different tumor types as proteasomes are present in all
eukaryotic cells; however it also has a number of myeloma
specific effects. One central mechanism by which bortezomib
functions in myeloma is via the inhibition of the breakdown of
inhibitory kappa B (IκB) and consequently stabilization of the
nuclear factor kappa B (NFκB) complex. This prevents NFκB
translocation to the nucleus with consequent inactivation of
multiple downstream pathways known to be important in
myeloma cell signaling (Karin et al 2002). It also decreases
the adhesion of the myeloma plasma cell to stromal cells which
increases sensitivity to apoptosis, as well as interrupting pro-
survival paracrine and autocrine cytokine loops in the bone
marrow microenvironment mediated by interleukin-6 (IL-6),
insulin-like growth factor 1 (IGF-1), vascular endothelial
growth factor (VEGF) and tumor necrosis factor-α (TNF-α)
(Hideshima et al 2001, 2003). Other effects in myeloma include
inhibition of angiogenesis, inhibition of DNA repair and
impairment of osteoclast activity (Rajkumar et al 2005). Tumor
cells appear to be more sensitive to the effects of proteasome
inhibition than normal cells due to a loss of checkpoint
mechanisms occurring during tumorgenesis; this means that
normal cells can usually recover as the inhibition is transient
and reversible.
Phase II and III clinical trials
Encouraging data from preclinical work (Hideshima et al
2001; LeBlanc et al 2002) and later Phase I studies in 2002
(Aghajanian et al 2002; Orlowski et al 2002) led to the
initiation of two phase II studies, Study of Uncontrolled
Myeloma Management with proteasome Inhibition Therapy
(SUMMIT) and Clinical Response and Efficacy Study of
bortezomib in the Treatment of refractory myeloma
(CREST) in multiple myeloma. In the SUMMIT trial, 202
patients with relapsed and refractory myeloma were treated
with single agent bortezomib for up to 8 cycles with an
overall response rate of 35% using the European Group for
Blood and Marrow Transplantation (EBMT) criteria (Blade
et al 1998). The response rate was increased to 50% with
the addition of dexamethasone on the day of and the day
after each injection of bortezomib (Richardson et al 2003).
Responses were independent of the type or number of
previous treatments, β2-microglobulin and chromosome 13
deletion status – factors which have previously influenced
response to other types of chemotherapy (Richardson,
Barlogie, et al 2005).
In the CREST study, 54 patients with relapsed myeloma
following one line of therapy were randomized to receive
bortezomib at either 1.0 mg/m
2 or 1.3 mg/m
2. Overall
response rates were 33% and 50% respectively (Jagannath
et al 2004). Again when dexamethasone was added, response
rates were higher at 44% and 62% respectively. The
incidence of adverse events was 20% lower in the group
receiving 1.0 mg/m2 suggesting that patients with
unacceptable toxicities receiving 1.3 mg/m
2 may be able to
tolerate a reduced dose of bortezomib and still achieve good
response rates.
The Assessment of Proteasome inhibition for EXtending
remissions (APEX) trial was a randomized phase III trial
set up to compare bortezomib with high dose dexamethasone
in 669 patients with multiple myeloma who had relapsed
after one or more therapies. The results showed a significant
survival benefit in the bortezomib group and the trial was
terminated early with the dexamethasone patients crossing
over to the bortezomib arm (Richardson et al 2005a). Overall
response rates were 38% in the bortezomib arm versus 18%
with dexamethasone alone (p<0.001). The results were
updated at American Society of Hematology (ASH) in
December 2005 based on a median follow up of 15.8 months
with a response rate of 43% to single agent bortezomib and
9% of patients achieving a complete response. Response
rates were higher in those who had only received one prior
line of therapy. At one year, overall survival was 80% in
those who had received bortezomib compared with 67% in
the dexamethasone arm, with a six month survival advantage
for patients treated with bortezomib (Richardson et al
2005b). It can be concluded from this phase III data thatTherapeutics and Clinical Risk Management 2006:2(3) 273
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bortezomib is superior to high dose dexamethasone as
second line treatment for relapsed myeloma.
Based on the results of these three trials in May 2003,
the FDA approved bortezomib for use in patients with
relapsed and refractory myeloma who had received 2 or
more prior therapies, and in April 2005 the European
Commission approved its use as a second-line treatment in
patients with multiple myeloma who have already undergone
or are unsuitable for bone marrow transplantation.
Clinical use
Bortezomib is usually given on an outpatient basis as a short
intravenous infusion on days 1, 4, 8, 11 of a 3 weekly cycle.
The 72 hour gap between infusions is important to allow
recovery of the proteasome inhibition in the normal cell.
The 10 day treatment-free period allows cell recovery and
prevents excessive side effects. A total of up to 8 cycles
may be given depending on response and toxicities.
On the basis of laboratory data showing an additive anti-
proliferative effect (Hideshima et al 2001), bortezomib was
combined with dexamethasone at a dose of 20 mg on the
day of and day after each injection. Although the initial phase
II trials were designed so that dexamethasone was added in
when there was failure to respond to 2 cycles of single agent
therapy, it can be argued given the synergistic effect of the
combination of bortezomib and dexamethasone, that
dexamethasone should be given to all patients who are able
to tolerate it from the start of treatment. In the SUMMIT
trial, 18% of patients who had a suboptimal response to
single agent bortezomib showed an improved response when
dexamethasone was added (Richardson et al 2003).
Data from SUMMIT and APEX suggest that in most
patients response to treatment is quick with the median time
to a first response 1.3 months (Richardson et al 2003, 2005a).
This suggests that if patients are not responding to treatment
after 4 courses of therapy (2 as single agent and 2 with the
addition of dexamethasone) then therapy should be changed.
Side effects and toxicities
Based on data from the SUMMIT trial, the most common
side effects are fatigue and weakness, gastrointestinal
disturbances (including nausea and vomiting, diarrhea,
constipation), thrombocytopenia and peripheral neuropathy
(Richardson et al 2003). It is recommended that bortezomib
should be withheld at the onset of grade 3 non-hematological
or grade 4 hematological toxicity, until the toxicity resolves
and then treatment restarted at a lower dose. Although
gastrointestinal disturbances and fatigue are the most
common side effects, peripheral neuropathy and
thrombocytopenia are the most problematic and clinically
significant and are therefore discussed in further detail
below.
Peripheral neuropathy
Bortezomib causes a predominantly sensory peripheral
neuropathy in approximately 30%–40% of patients
characterized by a burning sensation, paresthesias,
numbness and/or neuropathic pain (Richardson et al
2004; San Miguel et al 2005). Although this is reversible
in the majority of cases, care should be taken to avoid
causing permanent disabling neuropathy in patients and
at the onset of any grade 3 toxicity, bortezomib should
be withheld until symptoms have resolved and then
reinstated with a 25% dose reduction. In most instances
the neuropathy improves or resolves once treatment is
completed over a median of 3 months (San Miguel et al
2005). Based on experience from the phase II single agent
trials a number of recommendations for dose modification
in patients experiencing peripheral neuropathy as graded
by the National Cancer Institute common terminology
criteria for adverse events have been made. These are
summarized in Table 1 (NCI 2003).
Patients with pre-existing neuropathy may experience
worsening symptoms during treatment with bortezomib and
should therefore be monitored closely; however pre-existing
neuropathy, for example from previous thalidomide, should
not in itself preclude the use of bortezomib. Supportive
measures include the use of agents such as gabapentin and
amitryptiline, opiates, and referral to a specialist pain service.
It is important to ensure vitamin B and folate levels are
normal and not exacerbating the neuropathy. The actual
mechanism of nerve damage is not known and has been
difficult to establish as many patients in the trials had pre-
existing neuropathy. Hypotheses range from damage to the
peripheral nerve blood supply because of its anti-angiogenic
effect, a possibility of an increased inhibitory effect on the
proteasome within nerve endings and a dose related
disruption of normal homeostasis of cytosolic proteins
involved in axonal transport (EMEA 2004).
Postural hypotension can also be problematic and is
presumably related to an autonomic neuropathy. Patients
complaining of dizziness should have regular lying and
standing blood pressures taken and an increase in hydration
may be beneficial, for example 500 mls of normal salineTherapeutics and Clinical Risk Management 2006:2(3) 274
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with each bortezomib injection. Mineralcorticoids may be
useful and patients should be advised about rising slowly
from sitting or lying and not driving.
Thrombocytopenia
Thrombocytopenia is the most common hematological
toxicity occurring in approximately 30% of patients while
neutropenia and anemia have not been found to be
problematic (Lonial et al 2005). The development of
thrombocytopenia is dependent upon the baseline platelet
count, which in turn is related to the degree of bone marrow
plasma cell infiltration, and bone marrow toxicity/reserve
caused by previous lines of therapy.
Patients experience reductions in their platelet count of
around 60% and therefore do not usually develop grade 4
thrombocytopenia unless the baseline count is below 70. The
thrombocytopenia is transient and reversible showing a cyclical
pattern with platelets dipping at day 11 but returning to baseline
by day 1 of the next cycle. This is different to the pattern of
thrombocytopenia seen with other cytotoxic agents where
platelet counts drop after 1–2 weeks and can take up to 4 weeks
to recover or may not recover at all. This is due to a difference
in the mechanism of thrombocytopenia in proteasome
inhibition, which is related to a transient effect on
megakaryocyte function and platelet budding as opposed to
damage to marrow stem cells (Lonial et al 2005).
In the SUMMIT, trial only 2 patients had bleeding
episodes associated with thrombocytopenia, neither of
which were serious, and less than 15% of patients required
platelet transfusions (Richardson et al 2003). The SMPC
guidelines suggest that bortezomib should be withheld at
the onset of grade 4 hematological toxicity (hemoglobin
<6.5 g/dL, white blood cell <1.0 x 10
9/L with neutrophils
<0.5 x 109/L, platelets <25 x 109/L) and reinitiated once
symptoms have resolved. In practice patients experiencing
hematological toxicity can be managed safely with blood
and platelet support and granulocyte colony stimulating
factor (GCSF) and dose interruptions should not be
necessary provided patients are closely monitored. Full
blood counts should be checked prior to each injection of
bortezomib and again in the rest week if baseline platelet
counts are low. Platelet transfusion is recommended to keep
the platelet count above 30. If the thrombocytopenia is due
to marrow infiltration then patients responding to treatment
will generally experience a progressive increase in their
blood counts following the second cycle of therapy.
Use of prophylaxis
Although the incidence of varicella zoster infection is high
in multiply relapsed and refractory patients, the APEX trial
demonstrated an incidence of 13% in the bortezomib-treated
arm compared with 5% in the dexamethasone-treated arm
(p<0.001) (Richardson et al 2005a). Prophylactic acyclovir
should therefore be given to high-risk patients treated with
bortezomib.
Use in renal failure and liver
disease
A retrospective analysis of patients enrolled to the SUMMIT
and CREST trials examined the use of bortezomib in patients
with relapsed and refractory myeloma with renal impairment
(creatinine clearance less than 30 ml/min). This showed that
response rates and toxicities were similar to that obtained
for the whole trial population however the incidence of
serious adverse events was higher in patients with lower
creatinine clearance. In patients with creatinine clearance
(CrCl) >80  ml/min, 41% experienced serious adverse
events, compared with 51% of patients with CrCl 51–80  ml/
min and 60% of patients with CrCl <50 ml/min (Jagannath,
Barlogie, et al 2005). The data suggests that patients with
renal impairment can be safely and effectively treated with
bortezomib, however they should be closely monitored for
Table 1 Recommended dose modification for bortezomib-related neuropathy and/or neuropathic pain (NCI 2003)
Severity Signs and symptoms of peripheral neuropathy Dose modification
Grade 1 Asymptomatic; loss of deep tendon reflexes or No action
parathesia (including tingling) but not interfering with
function
Grade 2 or Sensory alteration or parathesia (including tingling) Reduce bortezomib to 1.0 mg/m2
Grade 1 with pain interfering with function but not with ADL (25% dose reduction)
Grade 3 or Sensory alteration or parathesia interfering with ADL Withhold bortezomib until toxicity resolves then
Grade 2 with pain restart at 0.7 mg/m2 (50% dose reduction)
Grade 4 Permanent sensory loss interfering with function Discontinue bortezomib
(disabling)
Abbreviations: ADL, activities of daily living.Therapeutics and Clinical Risk Management 2006:2(3) 275
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toxicities and managed accordingly. Up to 30% of patients
with myeloma have renal failure, the most common cause
of which is interstitial nephritis, and renal function may
improve following chemotherapy administration. It is
therefore important not to exclude this group of patients
when considering bortezomib treatment, particularly as
many other conventional chemotherapies are often directly
nephrotoxic and are either not suitable for patients with
impaired renal function or require dose modification in this
setting. There is limited data on the use of bortezomib in
patients with renal failure requiring dialysis, although a
number of anecdotal reports and a recent small study
(Chanan-Khan et al 2005) have suggested that it can be
delivered safely.
There is less data available on the use of bortezomib in
patients with impaired liver function although its use is not
recommended in patients with liver enzymes 2.5–3 times
the upper limits of normal as its metabolism may be
impaired. There has been one case of bortezomib-induced
severe hepatitis recently reported in the literature (Rosinol
et al 2005).
Combinations of bortezomib with
other chemotherapeutic agents
Early laboratory data showed that the combination of
bortezomib with dexamethasone resulted in an increase
myeloma cell kill in comparison to bortezomib alone
(Hideshima et al 2001). Data from the CREST trial
confirmed this synergistic effect in patients with an improved
response rate of 62% in patients treated with bortezomib
1.3 mg/m
2 with dexamethasone 20 mg on the day of and
day after injection versus 50% with bortezomib alone
(Jagnannath et al 2004). Further preclinical work has
demonstrated that bortezomib sensitizes myeloma cells to
the effects of other cytotoxic agents (Ma et al 2003;
Mitsiades et al 2003) and there are now numerous phase I
and II studies looking at bortezomib in combination with
different agents for both relapsed disease and as front line
treatment to establish whether response rates and survival
times can be improved further with manageable toxicities.
The results of these studies are summarized in Tables 2 and
3.
In the relapsed setting, the data is very encouraging with
bortezomib combination regimes repeatedly showing major
response rates of greater than 50% (although not all are
graded by EBMT criteria) without an increase in toxicity
(Table 2). Importantly these trials show that it is possible to
combine the agent with drugs known to cause peripheral
neuropathy (eg, thalidomide) or thrombocytopenia (eg,
melphalan) without an increase in these side effects,
although careful monitoring and a dose reduction may be
required. Phase I data combining bortezomib with
lenalidomide (Revlimid™), an immunomodulatory agent,
is particularly interesting especially as many of the patients
treated in this study demonstrated responses despite being
resistant previously to one or other of the agents
(Richardson, Schlossman, et al 2005).
To date the gold standard treatment for younger fitter
patients with myeloma is vincristine, adriamycin, and
dexamethasone (VAD), or cyclophosphamide, vincristine,
adriamycin, and methyl prednisolone (C-VAMP) induction
chemotherapy followed by high dose melphalan with
peripheral blood stem cell return. The major response rate
(complete response [CR] + partial response [PR]) for this
approach is 60% with up to 50% of patients achieving a
complete response after completion of the whole therapy
and 15% after completion of the induction phase (Alvares
et al 2005). Recent reports have suggested that thalidomide
and dexamethasone is superior to VAD as induction therapy
prior to transplantation, with response rates of 76% and 52%
respectively (p<0.001) (Cavo et al 2005). The early reports
of bortezomib in front line therapy indicate a response rate
of 80%–90% which compares very favorably to other
standard pre-transplant induction regimens. For example,
in the study by Wang et al (2005) response rates were 30%
higher than those observed previously among similar
patients treated with thalidomide and dexamethasone
(p<0.01). Importantly the data using bortezomib with
dexamethasone or bortezomib with doxorubicin and
dexamethasone (PAD) demonstrates that stem cell
mobilization is not impaired and that there is no increased
toxicity during the transplant procedure (Harousseau et al
2004; Jagannath, Durie, et al 2005; Oakervee et al 2005;
Wang et al 2005). Phase III trials are underway to compare
this to standard induction approaches, for example the
Stichting Hemato-Oncologie voor Volwassenen Nederland
(HOVON) group are assessing PAD prior to stem cell
transplant followed by maintenance therapy with bortezomib
compared with VAD prior to transplant with thalidomide
maintenance.
New regimens for non-transplant candidates also look
promising especially in the elderly where the Spanish group
have shown that it is possible to combine bortezomib with
melphalan and prednisolone (MP) (Mateos et al 2005). The
MP regimen, although the current gold standard, is known
only to induce responses in 60% of patients with less thanTherapeutics and Clinical Risk Management 2006:2(3) 276
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10% complete response and often takes up to nine months
to induce a stable disease phase (Facon et al 2006). The
early data in combination with bortezomib demonstrates a
response rate of 85% with manageable toxicities, although
a dose reduction was required in some cases due to
prolonged cytopenias (Berenson et al 2006). The
randomized phase III VISTA trial is currently underway to
compare bortezomib and MP to standard MP in newly
diagnosed myeloma patients not suitable for transplant.
Clinical trials are also underway looking at the use of
bortezomib in other hematological malignancies including
lymphoma, acute leukemia and solid tumors including non
small cell lung cancer, prostate, ovarian, and breast (Ludwig
et al 2005). So far results look promising particularly in
mantle cell lymphoma where a major response rate of 41%
in previously heavily treated patients was seen (Goy et al
2005).
Summary
The introduction of bortezomib in the treatment of myeloma
has been a major breakthrough, first in the relapsed setting
and increasingly as a front line approach prior to stem cell
transplantation as well as in combination with MP in patients
unsuitable for transplantation. It is able to induce responses
in previously refractory patients and results in an increased
progression free and overall survival in relapsed patients
when compared with dexamethasone treatment alone.
Following its approval by the US and European regulatory
authorities for the treatment of myeloma nearly 3 years ago,
there have been a large number of studies confirming these
initial results. It has become evident that proteasome
inhibition, due to its novel mechanism of action, is often
effective in cases previously refractory to other more
conventional treatments as well as in patients with high risk
disease as defined by cytogenetics, and that there is a
synergistic effect when bortezomib is added to other
chemotherapeutic agents. Experience shows that bortezomib
can be administered safely and effectively in the outpatient
setting provided clinicians use it at an appropriate stage in
an individual’s management, have an understanding of its
different mechanism of action and can manage toxicities
appropriately. Neuropathy is the most common dose limiting
toxicity and thrombocytopenia can generally be managed
with platelet transfusions without reducing or omitting
doses. Bortezomib is currently approved for use in the
relapsed setting post transplant or as a second line treatment
in patients unsuitable for transplantation, although as more
data becomes available it will inevitably be used routinely
as induction therapy in combination with other agents in
newly diagnosed patients. With the advent of bortezomib
and other new small molecules, the future for myeloma
patients looks promising as other ways of targeting myeloma
cells and the bone marrow microenvironment are exploited.
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